We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
CellMark agreed to a consent order banning the company from any involvement in manufacturing of products that treat, cure, mitigate or prevent cancer. Read More
Federal right-to-try legislation passed in the Senate and now awaiting a vote in the House would only minimally benefit patient access to investigational drugs and would delay the FDA’s approval process for new drugs, according to bioethicists at the University of Pennsylvania’s Department of Medical Ethics. Read More
The Federal Trade Commission took CellMark Biopharma to federal court for falsely advertising two of its supplements as “clinically proven” to treat cancer and cancer treatment side effects. Read More
A new CDER-funded study says the FDA is not taking full advantage of social media to communicate drug safety information — and should, for example, be making more use of Twitter in its campaigns. Read More
The FDA will prioritize the opioid crisis, innovation, and generic competition in the coming year, the agency said in a 2018 Strategic Policy Roadmap released Thursday. Read More